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Abstract 1 
This article aimed to assess the clinical effectiveness of non-hormonal targeted therapies 2 
(TTs) in terms of increase of median progression-free survival (PFS) and overall survival 3 
(OS) in receptor-positive metastatic breast cancer (MBC) patients by performing a systematic 4 
review and meta-analysis. We systematically searched relevant randomized controlled trials 5 
and extracted data about number of patients on targeted and comparator therapy, receptor 6 
status, line of treatment, median PFS and OS, p values, hazard ratios (HRs) and 95% 7 
confidence intervals (CI). Inverse variance was used to estimate pooled HRs, chi-square test 8 
for heterogeneity and Jadad scale for quality were applied. Thirty eight studies (n=17,192 9 
patients) were eligible for inclusion. TTs added 3.3 months to the median PFS [0.7–9.6; HRs 10 
0.74, 95% CI 0.71–0.77] of receptor-positive MBC patients and prolonged their median OS 11 
with 3.5 months [0–4.7; HRs 0.90, 95% CI 0.82–0.98]. The highest increase in median PFS 12 
of 3.6 months was found in HER2-/HR+ patients, while the highest increase in median OS of 13 
7.2 months was observed in HER2+/mixed hormone receptor (HR) status patients. First-line 14 
TTs were most effective in increasing the median PFS in the HR+/HER2- group with 2.0 15 
months, and in the HER2+/HR-mixed group by adding 4.7 months to the median OS. 16 
Second-line TTs were most effective for HER2-/HR+ patients by adding 2.6 months to their 17 
PFS, and for HER2+/HR-mixed patients by adding 3.1 months to their median OS. Albeit 18 
small, the gain in months of median PFS and median OS was significant. Importantly, the 19 
results reported show large variation, and thus routinely applying a personalized approach 20 
seems warranted. 21 
 22 
Keywords: breast neoplasm; molecular targeted therapy; human epidermal growth factor 23 
receptor 2; estrogen receptors; progesterone receptors; survival analysis. 24 
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Introduction 1 
 2 
Advanced breast cancer is encountered in around 5-10% of patients with primary breast 3 
cancers [1], and another 10% of the patients develop distant recurrence within 5 years after 4 
primary disease and treatment [2,3]. Once breast cancer has metastasized to distant locations, 5 
it is generally considered amenable to palliative rather than curative care. Therefore, the goals 6 
of treatment at this later stage are focused on delaying the progression of the metastatic 7 
disease, relief of cancer-related symptoms and maintaining quality of life [1]. 8 
The majority of patients with metastatic breast cancer (MBC) are subjected to targeted 9 
therapy (TT) depending on the presence of a positive receptor status of the metastasis (human 10 
epidermal growth factor receptor (HER2) and/or hormone receptor (HR) – estrogen (ER) and 11 
progesterone (PR) [1]. Targeted treatment entails anti-HER2 agents (for HER2-positive 12 
disease), hormone therapy and anti-HR agents alone or in combination (for HR-positive 13 
disease) [1]. Significant advances in molecular targeted therapies and the development of 14 
new treatment combinations can offer a personalized and less aggressive approach of 15 
managing patients with metastatic disease that have overexpressing receptor status [4,5]. 16 
Withholding certain a priori ineffective treatments in some patients while immediately 17 
switching to other last resort treatments in others can have a positive impact on their survival. 18 
TTs have been tested in randomized controlled trials (RCTs) to assess clinical effectiveness 19 
in terms of time to disease progression and overall survival [6]. Most of the investigated 20 
treatments suggest that TTs could prolong life of MBC patients [7]. However, the extent to 21 
which TTs could increase the survival of MBC patients is yet unclear. 22 
Previous systematic reviews and meta-analyses have demonstrated that the addition of TT to 23 
chemo- and endocrine therapies significantly improved the overall survival (OS) and the 24 
progression-free survival (PFS) of HER2-positive and/or HR+ MBC patients [6,7]. Others 25 
reported increased efficacy of trastuzumab in combination with chemotherapy on the median 26 
OS [8] and improved OS of these patients when treated with lapatinib [9]. Although these 27 
previous reviews clearly demonstrate that TTs improved survival, they did not estimate the 28 
absolute effects in terms of duration of time (i.e. months) added to the life of these patients. 29 
Since this information is crucial for future cost-effectiveness studies, the aim of this analysis 30 
was to assess the clinical effectiveness of non-hormonal TTs in terms of increase in months 31 
in median PFS and OS of patients diagnosed with advanced or MBC by performing a 32 
systematic review and meta-analysis of published RCTs. 33 
  34 
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Methods 1 
 2 
This systematic review adhered to the guidance of the Preferred Reporting Items for 3 
Systematic Reviews and Meta-Analyses (PRISMA) statement [10] and followed a 4 
predetermined search strategy and selection criteria developed by two reviewers (GHdB and 5 
RGKK). 6 
 7 
 8 
Data sources and search strategy 9 
A comprehensive search of PubMed was initially performed on 6 July 2015, and updated on 10 
21 December 2016. The search algorithm was designed by an experienced librarian (DGvI) 11 
and included the following keywords and Mesh terms: breast neoplasms, breast, survival 12 
analysis, survival rate, survival, treatment outcome, mortality, trastuzumab, trastuzumab 13 
emtansine, lapatinib, pertuzumab, bevacizumab, everolimus, palbociclib. 14 
 15 
 16 
Eligibility criteria 17 
Articles were considered if they described RCTs which enrolled women with advanced 18 
and/or metastatic breast cancer and compared approved by the Food and Drug Agency (FDA) 19 
and the European Medicines Agency (EMA) non-hormonal TTs (trastuzumab, trastuzumab 20 
emtansine, lapatinib, pertuzumab, bevacizumab, everolimus, palbociclib) to other types of 21 
treatment or placebo. Studies were selected if the reference arm also included TT or 22 
hormonal therapy, as long as the intervention arm included the approved TT of interest, and 23 
the arms did not compare one and the same TT. Only trials that reported the outcomes of 24 
interest (PFS and/or OS) were included irrespective of the phase of the study. The articles 25 
which used different types of study design and lacked original data (reviews, editorials, etc.) 26 
were excluded. Studies which were not reported in English or their abstract and full text 27 
could not be obtained were also excluded. In case of several articles describing the same trial, 28 
the most recent publication was selected and included in the analyses. 29 
 30 
 31 
Study selection and data extraction 32 
Three reviewers (MPO, ALR and RGKK) independently assessed each title and abstract for 33 
eligibility. Included trials were retrieved as full texts and screened for duplicates. 34 
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Disagreement at any level was resolved by consultation with a fourth reviewer (GHdB). The 1 
three reviewers independently performed the data extraction and retrieved study details from 2 
the articles by a predefined questionnaire which included type of trial, line of treatment, 3 
receptor status of the metastatic disease, targeted and comparator therapies, and number of 4 
patients. The extracted results of interest encompassed: time to outcome (PFS and OS) – 5 
median and range, p values, hazard ratios (HRs), and 95% confidence intervals (CI) (Table 1, 6 
Table 2, Figure 2 and Figure 3). HRs were defined as the risk of recurrence or further spread 7 
of the metastatic disease. PFS was defined as the time of randomization until the time of 8 
disease progression or death from any cause. OS was defined as the time from randomization 9 
until the time of death from any cause.  10 
 11 
 12 
Statistical analysis 13 
The HRs outcomes were pooled into a forest plot in Review Manager (RevMan) [11] to 14 
determine the overall HRs effect between the TTs and the comparator therapies. The pooled 15 
HRs were calculated by applying random effects model. The reported outcomes of interest 16 
(PFS and OS) from the studies were used to determine the median and the range of PFS and 17 
OS from all studies for the TT and the comparator arms. To test whether there was a 18 
difference in survival depending on the receptor status (HR or HER2), line of treatment or 19 
type of TT, subgroup-analyses were performed for HER2-positive and HR-positive groups of 20 
patients, per line of treatment and per type of TT. For this purpose all reported outcomes were 21 
transformed into months. Immature and interim PFS and OS results were not included into 22 
the analyses. A chi-square test for heterogeneity was used to test for homogeneity between 23 
studies and a p-value of 0.10 was applied [12]. 24 
 25 
 26 
Assessment of risk of bias 27 
The Jadad scale [13] was used to assess the quality of the selected RCTs. The mean and the 28 
median, and the range of the Jadad score was reported for all studies. 29 
  30 
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Results 1 
 2 
Selection of studies 3 
Six hundred and fifty three hits appeared in PubMed on 21 December 2016 with the search 4 
strategy described previously. Four hundred and fourty seven articles were excluded after 5 
screening the titles and abstracts as not matching the eligibility criteria. The full text of the 6 
remaining 206 articles was examined and 38 RCTs published in 40 articles which contained 7 
PFS and/or OS as outcome were identified as being eligible to be included in the review 8 
(n=17,192 patients, Figure 1) [14–53]. 9 
 10 
 11 
Type of targeted therapy 12 
The most commonly investigated TTs in the selected RCTs including large groups of patient 13 
population were trastuzumab, bevacizumab and lapatinib, while trastuzumab emtansine, 14 
pertuzumab, everolimus and palbociclib were less tested and the number of patients included 15 
was smaller (Table 1). 16 
 17 
 18 
Progression-free survival – hazard ratios, median and range 19 
The pooled hazard ratio was 0.74 (95% CI 0.71–0.77), indicating that overall TTs improved 20 
significantly the median PFS in patients with receptor-positive MBC (Figure 2). TTs 21 
increased PFS with 37%. In general, TTs had longer median PFS than the comparator 22 
strategies. The median PFS for all studies in receptor-positive MB C patients was 9.0 months 23 
[2.6–24.8] for the TT arms and 5.7 months [1.9–15.2] for the comparator arms. Overall the 24 
application of TTs in receptor-positive MBC patients added 3.3 months [0.7–9.6] to the 25 
median PFS of these patients (Table 1, Table 2). 26 
The analysis for the subgroup of patients with HER2-positive and mixed HR status disease 27 
demonstrated that the use of TTs added 2.4 months [0.7–3.5] to the median PFS of these 28 
patients (HRs 0.76, 95% CI 0.72–0.80). First-line TTs in this subgroup showed the same PFS 29 
as compared to second-line and beyond TTs (Table 1, Table 2, Figure 2). Everolimus and 30 
trastuzumab emtansine demonstrated longer median PFS in MBC patients with HER2-31 
positive and HR-mixed disease as compared to trastuzumab and pertuzumab containing 32 
regimens, and lapatinib. 33 
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The analysis for the subgroup of patients with HER2-negative and HR-positive disease 1 
revealed that the use of TTs added 3.6 months [1.8–10.3] to the PFS of these patients (HRs 2 
0.71, 95% CI 0.67–0.75). First-line TTs in this subgroup showed shorter median PFS as 3 
compared to second-line and beyond TTs (Table 1; Figure 2). In the same subgroup 4 
palbociclib demonstrated the highest increase in median PFS, followed by bevacizumab and 5 
everolimus (Table 1, Table 2). 6 
The heterogeneity of all studies was 84%, Chi
2
=250.59 and p<0.00001, indicating substantial 7 
diversity among studies. 8 
 9 
 10 
Overall survival – hazard ratios, median and range 11 
The pooled hazard ratio was 0.90, 95% CI (0.82–0.98), indicating that overall TTs improved 12 
significantly the median OS in patients with receptor-positive MBC (Figure 3). TTs increased 13 
the median OS with 12%. In general, the investigational study arms including TTs showed 14 
longer median OS than the comparator strategies. The median OS of all studies in receptor-15 
positive MBC patients was 28.6 months [14–56.5] for the TT arms and 25.1 months [9.5–16 
51.8] for the comparator arms. The application of TTs in receptor-positive MBC patients 17 
added 3.5 months [0–4.7] to their survival (Table 1, Table 2). 18 
The analysis for the subgroup of patients with HER2-positive and mixed HR status disease 19 
demonstrated that the use of TTs added 7.2 months [4.5–15.7] to the median OS of these 20 
patients (HRs 0.89, 95% CI 0.77–1.02). First-line TTs showed longer median OS as 21 
compared to second-line and beyond TTs and added more to the survival of these patients 22 
(4.7 months first-line vs. 3.1 months second-line – Table 1, Table 2, Figure 3). In the same 23 
subgroup investigational regimens containing trastuzumab, pertuzumab, trastuzumab 24 
emtansine and lapatinib demonstrated superior median OS than the comparator arms’ 25 
regimens (Table 1, Table 2). 26 
The analysis for the subgroup of patients with HER2-negative and HR-positive disease 27 
revealed that the use of TTs added 3.6 months [0.6–not estimated] to the median OS of these 28 
patients (HRs 0.91, 95% CI 0.84–0.99). First-line TTs showed longer median OS as 29 
compared to second-line and beyond TTs, but did not add to the survival of these patients, 30 
(Table 1, Table 2, Figure 3). In the same subgroup bevacizumab demonstrated the highest 31 
increase in median OS. Lapatinib and palbociclib showed improved median OS, while 32 
everolimus did not reach projected OS (Table 1, Table 2). 33 
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The heterogeneity of all studies was 59%, Chi
2
=64.06 and p<0.0001, indicating moderate to 1 
substantial diversity among studies. 2 
 3 
 4 
Assessment of risk of bias 5 
The mean Jadad score of the RCTs used in this review was 3.0 (median 3, range 1 – 5). 6 
  7 
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Discussion 1 
This analysis demonstrated that the application of non-hormonal TTs in metastatic breast 2 
cancer results in an increase in PFS which is most prominent in patients with HER2-negative 3 
and HR-positive disease, whereas OS increase was most prominent in patients with HER2-4 
positive disease and mixed HR status disease. 5 
 6 
The pooled HRs showed that TTs significantly prolonged the median PFS and OS as 7 
compared to other therapies. However, in absolute length of time (i.e. months) these median 8 
prolongations of PFS and OS appeared less impressive. TTs were most beneficial for the 9 
median PFS of patients with HER2-negative and HR-positive disease and for the median OS 10 
of patients with HER2-positive and mixed HR-disease. It should be noted, though, that a 11 
large variation was observed in the minimum and maximum ranges of PFS and OS for both 12 
the TT and the comparator arms, as well as per receptor status and line of treatment. 13 
Therefore, determination of the receptor status of the tumors is important for personalized 14 
selection of therapy. 15 
 16 
Having in mind the incidence of breast cancer and the fact that MBC is considered incurable
 
17 
[1], even a small increase in PFS and OS could be beneficial for patients with distant relapse. 18 
Our findings confirmed the effectiveness of non-hormonal TTs in MBC patients with 19 
receptor positive, either HER2 or HR, disease. Findings by other studies suggested that 20 
increase in survival benefits was accompanied by increase in adverse effects [6,7,54,55], 21 
which can impact negatively the quality of life of MBC patients. Therefore, in clinical 22 
practice it is important to consider different dose adjustments and different combinations of 23 
treatment options. 24 
 25 
A review by Kawalec and colleagues [6] showed similar results regarding the HRs for the 26 
PFS in previously untreated MBC patients. They reported that the combination of TT and 27 
endocrine therapy significantly improved PFS in the same patient group and the combination 28 
of TT and chemotherapy significantly improved OS in HER2-positive patients. However, in 29 
patients with HER2-negative and/or HR-negative disease adding TT to chemotherapy did not 30 
improve PFS and OS [6], which contradicted our finding for first-line treatment of HER2-31 
negative and HR-positive patients. 32 
All 13 RCTs included in the review of Kawalec et al were also included in this work and the 33 
mean Jadad scores of both reviews were comparable 2.7 (Kawalec et al) versus 3.0 (this 34 
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work). However, they did not estimate the median PFS and did not pool overall HRs for all 1 
TTs. In addition they only included studies of previously untreated MBC patients, i.e. first-2 
line of treatment [6]. 3 
Two other reviews regarding the application of bevacizumab and chemotherapy versus 4 
chemotherapy alone included four and seven RCTs, respectively, in their meta-analyses and 5 
found HRs for PFS of 0.70 (95% CI 0.64–0.77) and 0.75 (95% CI 0.68–0.84). The results of 6 
these reviews were comparable to ours 0.77 (95% CI 0.72–0.82), based on 9 RCTs. All RCTs 7 
included in these reviews were also included in our analysis. For the RCTs in these reviews 8 
Jadad scores were not available for comparison [54,55]. 9 
Another recently published systematic review of Mendes et al [7] concluded that HER2-10 
directed therapies had beneficial impact on OS of patients with HER2-positive MBC. 11 
Importantly, they considered only phase III trials and did not estimate the absolute 12 
contribution of TTs to PFS and OS in terms of months, or with respect to receptor status of 13 
the MBC and line of treatment [7]. 14 
 15 
 16 
TTs and the development of new treatment combinations offer a personalized therapeutic 17 
approach of which may be more effective and prolong the life expectancy of MBC patients. 18 
However, in the last decades these new therapies account for a substantial increase in 19 
healthcare expenditures for MBC treatment and the cost-effectives in terms of monetary units 20 
spent per life-year-gained and quality-adjusted life years (QALYs) varies largely [56]. In 21 
these analyses the variables that have a significant impact on the cost-effectiveness 22 
estimations are the price of the therapies, and the survival benefit and gain in QALYs [57]. 23 
Therefore, it is important to assess the effects of TTs in terms of PFS and OS, and QALYs, 24 
and to weight them against incurred costs. 25 
 26 
 27 
This review had several strengths and limitations. To our knowledge, it is the first to estimate 28 
median PFS and OS and assess the extent to which TTs contribute to PFS and OS 29 
prolongation in terms of months. In addition, it showed pooled HRs for all TTs and per 30 
receptor status of the metastatic disease and line of treatment. This review also assessed the 31 
quality of the included RCTs by applying the Jadad scale. A limitation of this study was that 32 
it used published data from the RCTs to pool HRs and estimate median and range of PFS and 33 
OS which could result in an overestimation of the results as studies with unfavorable results 34 
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are less often published [58]. Not all publications included in this review reported HRs, PFS 1 
and OS or median survival times including ranges. Another limitation was that the HER2-2 
negative patient population was predominantly positive on the ER-status and/or the PR-3 
status, and was reported as being HR-receptor positive in the trials. There were, however, 4 
also some HR-negative patients which could have an impact on the estimated survival 5 
periods. In addition, studies which evaluated therapies which have not yet been approved by 6 
the FDA and/or the EMA for use in metastatic breast cancer (e.g. sorafenib, sunitinib and anti 7 
PI3K) were not included. Furthermore, in some of the trials the comparator arm also included 8 
TTs which albeit different from the investigational one, might have contributed to the 9 
underestimation of the survival periods in the intervention group. Ideally TT should be 10 
compared to placebo to evaluate its full potential and impact on PFS and OS. However, such 11 
studies were rare to find mainly due to ethical concerns regarding patients’ access to 12 
treatment.   13 
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Conclusion 1 
Estimated HRs show better efficacy of TTs in terms of improved PFS and OS as compared to 2 
other therapeutic approaches, and although the gain in median PFS and OS is statistically 3 
significant, the absolute numbers are small (3.3 months [0.7–9.6] and 3.5 months [0–4.7]). As 4 
the reported data regarding gain in PFS and OS have a relatively large variation, a 5 
personalized approach and careful consideration of the patient characteristics, as well as 6 
assessment and re-assessment of the receptor status of the primary and metastatic disease 7 
should be warranted prior to the application of TT to an individual MBC patient [64]. This 8 
seems particularly appropriate as effects in terms of PFS and OS, as well as QALYs, have an 9 
impact on costs and cost-effectiveness of TTs in MBC. 10 
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Table 1. Progression-free survival (PFS) and overall survival (OS) in months for non-hormonal 1 
targeted therapy (TT) versus comparator therapy (CT) in receptor positive metastatic breast cancer 2 
(MBC) disease (38 studies, n=17,192 patients) 3 
 4 
Refere
nce 
Type of RCT 
Line of 
treatm
ent 
Receptor 
status 
Targeted (TT) 
vs. comparator 
therapy (CT) 
(number of pts 
in each arm) 
OS months PFS months 
Jada
d 
scor
e TT CT TT CT 
HER2-positive and mixed HR status disease 
Pertuzumab and / or trastuzumab containing regimens 
27 LUX-Breast 
1 study: 
phase III 
2 HER2-
positive 
Trastuzumab + 
vinorelbine 
(169) VS Afatinib 
+ vinorelbine 
(339) 
28.6 20.
5 
5.6 5.5 3 
16 EGF104900 
study: 
open-label, 
phase III 
2 HER2-
positive, 
51% ER- 
and PR-
negative 
Lapatinib + 
trastuzumab 
(146) VS 
Lapatinib (145) 
14 9.5 2.6 1.9 2 
24 open-label, 
phase II 
1 HER2-
positive, 
32-49% ER- 
and PR-
negative, 
36% ER- 
and PR-
positive 
Paclitaxel + 
trastuzumab 
(63) VS 
Paclitaxel (61)  
NA NA 9.9 6.7 3 
28 eLEcTRA 
study: open 
label, phase 
III 
1 HER2-
positive 
and HR-
positive 
Sub-group 
of 35 HER2-
negative 
and HR-
positive pts 
on 
Letrozole 
alone 
Letrozole + 
trastuzumab 
(26) VS Letrozole 
alone (31/35) 
NA NA 14.1 3.3/1
5.2 
1 
31 TAnDEM 
study: 
open-label, 
phase III 
1 HER2- and 
HR-positive 
Trastuzumab + 
anastrozole 
(103) VS 
Anastrozole 
34.1 28.
6 
4.8 2.4 3 
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(104) 
36 M77001 
study: 
open-label, 
comparativ
e, phase II 
1 HER2-
positive, 
41-56% ER-
and/or PR-
positive 
Trastuzumab + 
docetaxel (92) 
VS Docetaxel 
alone (94) 
31.2 22.
7 
11.7 6.1 2 
45 pivotal, 
open-label, 
phase III 
study 
1 HER2-
positive 
Chemotherapy + 
trastuzumab 
(235) VS 
Chemotherapy 
(234) 
25.4 20.
3 
7.6 4.6 2 
46 CLEOPATRA 
study: 
double-
blind, 
placebo-
controlled, 
phase III 
1 HER2-
positive, 
388 pts ER- 
or PR-
positive, 
408 pts ER- 
or PR-
negative 
Pertuzumab + 
trastuzumab + 
docetaxel (402) 
VS Placebo + 
trastuzumab + 
docetaxel (406) 
56.5 40.
8 
18.7 12.4 5 
50, 51 A German 
Breast 
Group 
26/Breast 
Internation
al Group 
03-05 
study: 
open-label, 
phase III 
2 HER2-
positive 
(includes 
LABC) 
Trastuzumab + 
capecitabine 
(78) VS 
Capecitabine 
(78) 
24.9 20.
6 
8.2 5.6 3 
Everolimus 
14 BOLERO-3 
study: 
double-
blind, 
placebo-
controlled, 
phase III 
2 HER2-
positive, 
53% ER-
positive, 
47% ER-
negative, 
37% PR-
positive, 
61-62% PR-
negative 
Everolimus + 
vinorelbine + 
trastuzumab 
(284) VS Placebo 
+ vinorelbine + 
trastuzumab 
(285) 
NA NA 7.0 5.8 5 
29 BOLERO-1 
study: 
double-
blind, 
placebo-
controlled, 
phase III 
1 HER2-
positive 
(includes 
invasive 
LRBC), 57% 
HR-positive, 
43 HR-
Everolimus + 
trastuzumab + 
paclitaxel (480) 
VS Placebo + 
trastuzumab + 
paclitaxel (239) 
NA NA 15.0 14.5 5 
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negative 
Trastuzumab emtansine containing regimens 
30 TDM4450g 
study: 
phase II, 
open-label 
1 HER2-
positive 
(includes 
recurrent 
LABC), 49-
54% ER- 
and/or PR-
positive, 
41-48% ER- 
and PR-
negative 
Trastuzumab 
emtansine (67) 
VS Trastuzumab 
+ docetaxel (70) 
NA NA 14.2 9.2 3 
32 TH3RESA 
study: 
open-label, 
phase III 
2 HER2-
positive, 
51-52% ER-
positive 
and/or PR-
positive, 
43-46% ER-
negative 
and PR-
negative 
Trastuzumab 
emtansine (404) 
VS Treatment of 
physician’s 
choice (198) 
15.8 12 6.2 3.3 3 
48 EMILIA 
study: 
open-label, 
phase III 
2 HER2-
positive 
(includes 
LABC), 53-
57% ER- 
and/or PR-
positive, 
41-45% ER- 
and/or PR-
negative 
Trastuzumab 
emtansine (495) 
VS Lapatinib 
plus 
capecitabine 
(496) 
30.9 25.
1 
9.4 5.8 3 
Lapatinib containing regimens 
19 phase III 
study 
2 HER2-
positive, 
49-50% ER- 
and PR-
negative, 
46-48 ER- 
and PR-
positive, 
(includes 
LABC) 
Lapatinib + 
capecitabine 
(207) VS 
Capecitabine 
monotherapy 
(201) 
17.2 14.
8 
6.1-
7.8 
4.7-
4.9 
2 
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23 MA.31 
study: 
open-label, 
phase III 
1 HER2-
positive, 
65% ER-
positive, 
31% ER-
negative, 
34% PR-
positive, 
60% PR-
negative 
Lapatinib + 
taxane followed 
by lapatinib 
(326) VS 
Trastuzumab + 
taxane followed 
by trastuzumab 
(326) 
NA NA 9.0 11.3 3 
26 EGF104535 
study: 
double-
blind, 
placebo-
controlled, 
phase III 
1 HER2-
positive, 
ER- and/or 
PR-positive 
or unknown 
Lapatinib + 
paclitaxel (222) 
VS Placebo + 
paclitaxel (222) 
27.8 20.
5 
9.7 6.5 4 
35 NCT007771
01 study: 
open-label, 
phase II 
2 HER2-
positive 
(includes 
LABC), 40-
44% ER-
positive, 
27-28% PR-
positive 
Lapatinib + 
capecitabine 
(116) VS 
Neratinib (117)  
23.6 19.
7 
6.8 4.5 
 
2 
41 CEREBEL 
(EGF111438
) study: 
open-label, 
phase III 
2 HER2-
positive, 
47% ER-
positive, 
52% ER-
negative, 
33% PR-
positive, 
61% PR-
negative 
Lapatinib + 
capecitabine 
(271) VS 
Trastuzumab + 
capecitabine 
(269) 
22.7 27.
3 
6.6 8.1 3 
44 EGF30008 
study: 
double-
blind, 
placebo-
controlled, 
parallel 
group, 
phase III 
1 HER2- and 
HR-positive 
Lapatinib + 
letrozole (111) 
VS Letrozole + 
placebo (108) 
33.3 32.
3 
8.2 3.0 4 
Bevacizumab containing regimens 
25 AVEREL 
study: 
open-label, 
1 HER2-
positive 
(includes 
Bevacizumab + 
trastuzumab + 
docetaxel (216) 
38 38 16.5 13.7 2 
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phase III LRBC), 51-
53% ER- 
and/or PR-
positive 
VS Trastuzumab 
+ docetaxel 
(208) 
HR-positive and HER2-negative disease 
Bevacizumab containing regimens 
17 RIBBON-2 
study: 
double-
blind, 
placebo-
controlled, 
phase III 
2 HER2-
negative 
(84-85%), 
HR-positive 
(72-73%) 
Bevacizumab + 
chemotherapy 
(459) VS Placebo 
+ chemotherapy 
(225) 
NA NA 7.2 5.1 4 
34 LEA study: 
open-label, 
phase III 
1 HER2-
negative, 
HR-positive 
Endocrine 
therapy + 
bevacizumab 
(191) VS 
Endocrine 
therapy (189) 
52.1 51.
8 
19.3 14.4 2 
37 AVADO 
study: 
double-
blind, 
placebo-
controlled 
1/2 HER2-
negative 
(includes 
LRBC), 76-
78% ER and 
PR-positive 
All groups 
Docetaxel + 
Bevacizumab 
(7.5 or 15 
mg/kg) 
(248/247) VS 
Docetaxel + 
placebo (241) 
30.8/3
0.2 
31.
9 
9.0/1
0.0 
8.1 4 
38 phase III 
study 
2 Over 40% 
ER-positive, 
over 30% 
PR-positive, 
over 20% 
HER2-
positive 
Bevacizumab + 
capecitabine 
(232) VS 
Capecitabine 
(230) 
15.1 14.
5 
4.9 4.2 2 
39 E2100 
study: 
open-label, 
phase III 
1/2 Over 90% 
HER2-
negative, 
over 60% 
ER-positive, 
over 50% 
PR-negative 
Paclitaxel + 
bevacizumab 
(368) VS 
Paclitaxel alone 
(354) 
26.7 25.
2 
11.8 5.9 2 
42 open-label 
phase III 
study 
1 HER2-
negative 
advanced 
breast 
cancer 
Paclitaxel + 
bevacizumab 
(243) VS 
Paclitaxel + 
sunitinib (242) 
NA NA 9.2 7.4 4 
43 RIBBON-1 1 HER2- Bevacizumab + NA NA 8.6- 5.7-8 2 
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study: 
double-
blind, 
placebo-
controlled, 
phase III 
negative 
(includes 
LRBC), 74-
77% HR-
positive 
chemotherapy 
(824) VS Placebo 
+ chemotherapy 
(413) 
9.2 
49 TANIA 
study: 
open-label, 
parallel-
group, 
phase III 
2 HER2-
negative 
(includes 
LRBC), 76-
80% ER- 
and/or PR-
positive 
Bevacizumab + 
chemotherapy 
(247) VS 
Chemotherapy 
alone (247) 
NA NA 6.3 4.2 3 
Lapatinib containing regimens 
18 CALGB 
40302 
study: 
double-
blind, 
placebo-
controlled 
phase III 
2 ER-positive 
and/or PR-
positive, 
78-84% 
HER2-
negative, 
16-21% 
HER2-
positive 
Fulvestrant + 
lapatinib (148) 
VS Fulvestrant + 
placebo (147) 
30 26.
4 
4.7 3.8 4 
20 EGF30001 
study: 
double-
blind, 
placebo-
controlled, 
phase III 
1 HER2-
negative/H
ER2-
untested, 
44-50% HR-
positive 
Paclitaxel + 
lapatinib (291) 
VS Paclitaxel + 
placebo (288) 
22.8 20.
0 
6.7 5.3 3 
Everolimus containing regimens 
15 GINECO 
study: 
open-label, 
phase II 
1/2 HR-positive, 
93-98% 
HER2-
negative 
Everolimus + 
tamoxifen (54) 
VS Tamoxifen 
alone (57) 
NA 32.
9 
8.6 4.5 2 
33 RADAR 
study: 
double-
blinded, 
placebo-
controlled, 
phase II, 
discontinua
tion study, 
8-weeks 
run-in 
phase on 
everolimus 
1/2 93% ER 
and/or PR 
positive, 7% 
both ER, PR 
negative, 
HER2-
negative, 
patients 
with bone 
metastases 
only 
Everolimus (18) 
VS Placebo (21) 
NA NA 8.5 2.9 3 
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prior to 
randomizati
on 
40, 53 BOLERO-2 
study: 
double-
blind, 
placebo-
controlled, 
phase III,  
2 100% ER-
positive, 
72% PR-
positive, 
HER2-
negative 
Everolimus + 
exemestane 
(485) VS Placebo 
+ exemestane 
(239) 
31.0 26.
6 
11 4.1 3 
52 phase II 
trial (Sarah 
Cannon 
Research 
Institute), 
placebo-
controlled 
1 HER2-
negative, 
79% ER-
positive 
and/or PR-
positive, 
21% ER-
negative 
and PR-
negative 
Everolimus + 
paclitaxel/carbo
platin (56) VS 
Placebo + 
paclitaxel/carbo
platin (57) 
17.5 19.
6 
9.1 7.1 2 
Palbociclib containing regimens 
22 PALOMA-
1/TRIO-18: 
open-label, 
phase II 
study 
1 ER-positive, 
HER2-
negative 
Palbociclib + 
letrozole (84) VS  
Letrozole alone 
(81) 
37.5 33.
3 
20.2 10.2 3 
21 PALOMA-2 
study: 
double-
blind, 
phase III 
1 ER-positive, 
HER2-
negative 
Palbociclib + 
letrozole (444) 
VS Placebo + 
letrozole  (222) 
NA NA 24.8 14.5 3 
47 PALOMA3 
study: 
double-
blind, 
phase III  
2 ER-positive 
and PR-
positive 
(63.8-
68.6%), ER-
positive 
and PR-
negative 
(26.2-
27.6%), 
HER2-
negative 
Palbociclib + 
fulvestrant (347) 
VS Placebo + 
Fulvestrant 
(174) 
NA NA 9.2 3.8 5 
 1 
  2 
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Table 2. Median and range of progression-free survival (PFS) and overall survival (OS) in months for 1 
non-hormonal targeted therapy (TT) versus comparator therapy (CT) in receptor positive metastatic 2 
breast cancer (MBC) disease (38 studies, n=17,192 patients) 3 
 Overall survival – median [range] PFS – median [range] 
 TT CT TT CT 
HER2-positive and mixed HR status disease 
 
   Whole subgroup 27.8 [14.0–56.5] 20.6 [9.5–40.8] 8.2 [2.6-18.7] 5.8 [1.9–15.2] 
 7.2 [4.5–15.7] 2.4 [0.7–3.5] 
 
   First-line 33.3 [25.4–56.5] 28.6 [20.3–40.8] 10.7 [4.8–18.7] 9.2 [2.4–15.2] 
 4.7 [not estimable] 1.5 [not estimable] 
 
   Second-line 23.2 [14.0–30.9] 20.1 [9.5–27.3] 6.7 [2.6–9.4] 5.2 [1.9–8.1] 
 3.1 [not estimable] 1.5 [0.7– not estimable] 
 
   Trastuzumab and 
   pertuzumab 
28.6 [14.0–56.5] 20.6 [9.5–40.8] 7.6 [2.6–18.7] 5.6 [1.9–15.2] 
 
   Trastuzumab 
   emnatasine 
23.4 [15.8–30.9] 18.6 [12.0–25.1] 9.4 [6.2–14.2] 5.8 [3.3–9.2] 
 
   Lapatinib 23.6 [17.2–33.3] 20.5 [14.8–32.3] 7.5 [6.1–9.7] 5.6 [3.0–11.3] 
 
   Everolimus [not estimable] [not estimable] 11.0 [7.0–15.0] 10.1 [5.8–14.5] 
     
HR-positive and HER2-negative disease 
 
   Whole subgroup 30.0 [15.1–52.1] 26.4 [14.5–51.8] 9.1 [4.7–24.8] 5.5 [2.9–14.5] 
 3.6 [not estimable] 3.6 [1.8–10.3] 
 
   First-line 30.2 [17.5–52.1] 31.9 [19.6–51.8] 9.2 [6.7–24.8] 7.3 [2.9–14.5] 
 [not estimable] 2.0 [not estimable] 
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   Second-line 22.6 [15.1–30.0] 20.5 [14.5–26.4] 6.8 [4.7–11.0] 4.2 [3.8–5.1] 
 2.1 [0.6–3.6] 2.6 [0.9–5.9] 
     
   Bevacizumab 30.2 [15.1–52.1] 28.6 [14.5–51.8] 9.1 [4.9–19.3] 5.9 [4.2–14.4] 
     
   Lapatinib 26.4 [22.8–30.0] 23.2 [20.0–26.4] 5.7 [4.7–6.7] 4.6 [3.8–5.3] 
     
   Everolimus [not estimable] [not estimable] 8.9 [8.5–11.0] 4.3 [2.9–7.1] 
     
   Palbociclib [not estimable] [not estimable] 20.2 [9.2–24.8] 10.2 [3.8–14.5] 
     
All subgroups 28.6 [14.0–56.5] 25.1 [9.5–51.8] 9.0 [2.6–24.8] 5.7 [1.9–15.2] 
Overall increase 3.5 [0–4.7] 3.3 [0.7–9.6] 
 
 1 
  2 
  
Figure 1. Flow diagram
  
Figure 2. Progression free survival - Forest plot
  
Figure 3. Overall survival - Forest plot
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Highlights: 1 
 Non-hormonal targeted therapies demonstrated better efficacy as compared to other 2 
treatments. 3 
 Non-hormonal targeted therapies could potentially prolong progression-free and 4 
overall survival in metastatic breast cancer patients with positive receptor status of the 5 
disease. 6 
 As pooled data suggests large variation in survival a prior selection of patients for 7 
therapy based on their receptor status is warranted and could provide personalized 8 
treatment management. 9 
 10 
